<qa>  What is the purpose of this single center, single arm open label study?This single center, single arm open label study is designed to assess the safety and efficacy of using high dose of Icotinib Conmana as a way to treat patients with non-small cell lung cancer that progressed after routine gefitinib therapy by progression-free survival, as well as overall survival and disease control rate. The adverse events and adverse reaction are evaluated as well. 